Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:8:505-510.
doi: 10.1016/j.toxrep.2021.03.003. Epub 2021 Mar 9.

Use of ivermectin in the treatment of Covid-19: A pilot trial

Henrique Pott-Junior  1 , Mônica Maria Bastos Paoliello  2 , Alice de Queiroz Constantino Miguel  3 , Anderson Ferreira da Cunha  4 , Caio Cesar de Melo Freire  4 , Fábio Fernandes Neves  1 , Lucimar Retto da Silva de Avó  1 , Meliza Goi Roscani  1 , Sigrid De Sousa Dos Santos  1 , Silvana Gama Florêncio Chachá  1
Affiliations

Use of ivermectin in the treatment of Covid-19: A pilot trial

Henrique Pott-Junior et al. Toxicol Rep. 2021.

Retraction in

Abstract

Objectives: In this randomized open-label trial pilot study we assessed the antiviral effects and safety of various doses of ivermectin in patients with mild clinical symptoms of COVID-19.

Methods: Patients were randomly assigned to receive standard of care (SOC) treatment at hospital admission; SOC plus ivermectin 100 mcg/kg; SOC plus ivermectin 200 mcg/kg; or SOC plus ivermectin 400 mcg/kg. The primary assessed endpoint was the proportion of patients who achieved two consecutive negative SARS-CoV-2 RT PCR tests within 7 days of the start of the dosing period. This study was registered at ClinicalTrials.gov (NCT04431466).

Results: A total of 32 patients were enrolled and randomized to treatment. SOC treatment together with ivermectin did not result in any serious adverse events. All patients exhibited a reduction in SARS-CoV-2 viral load within 7 days; however, those who received ivermectin had a more consistent decrease as compared to the SOC alone group, characterized by a shorter time for obtaining two consecutive negative SARS-CoV-2 RT PCR tests.

Conclusions: Ivermectin is safe in patients with SARS-CoV-2, reducing symptomatology and the SARS-CoV-2 viral load. This antiviral effect appears to depend on the dose used, and if confirmed in future studies, it suggests that ivermectin may be a useful adjuvant to the SOC treatment in patients with mild COVID-19 symptoms.

Keywords: COVID-19; Ivermectin; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Patient flow diagram. Patients with COVID-19 were followed for 28 days, with intermediate visits during follow-up days 1 through 7, and returned for follow-up visit 3 weeks after the end of the study dosing period.
Fig. 2
Fig. 2
Mean changes in cycle threshold values for (A) Pooled intervention groups (SOC vs Pooled ivermectin), (B) Individual groups during study dosing period.
Fig. 3
Fig. 3
Group-wise median cycle threshold reduction values from day 1 to 7.
See this image and copyright information in PMC

References

    1. Banerjee K., Nandy M., Dalai C.K., Ahmed S.N. The Battle against COVID 19 pandemic: what we need to know Before we "test fire" ivermectin. Drug Res. (Stuttg) 2020;70(August (8)):337–340. doi: 10.1055/a-1185-8913. - DOI - PMC - PubMed
    1. Lehrer S., Rheinstein P.H. Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. In Vivo. 2020;34(September-October(5)):3023–3026. doi: 10.21873/invivo.12134. - DOI - PMC - PubMed
    1. Sen Gupta P.S., Biswal S., Panda S.K., Ray A.K., Rana M.K. Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-alpha with in-vitro effective drug ivermectin. J. Biomol. Struct. Dyn. 2020;28:1–10. doi: 10.1080/07391102.2020.1839564. October. - DOI - PMC - PubMed
    1. Siddiqui A.J., Jahan S., Ashraf S.A. Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2. J. Biomol. Struct. Dyn. 2020;5:1–14. doi: 10.1080/07391102.2020.1802345. August. - DOI - PMC - PubMed
    1. Caly L., Druce J.D., Catton M.G., Jans D.A., Wagstaff K.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178 doi: 10.1016/j.antiviral.2020.104787. June. - DOI - PMC - PubMed

Publication types

Associated data

LinkOut - more resources